Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 916 to 930 of 1397 results for 0

  1. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

    Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

  2. Mental health problems in people with learning disabilities: prevention, assessment and management (NG54)

    This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

  3. PROPATEN heparin-bonded vascular graft for peripheral arterial disease (MIB42)

    NICE has developed a medtech innovation briefing (MIB) on the PROPATEN heparin-bonded vascular graft for peripheral arterial disease

  4. What is the optimal timeframe for starting parenteral nutrition in term babies who are critically ill or require surgery?

    recommendations. The committee agreed that all preterm babies born before 31+0 weeks should receive parenteral nutrition from birth...

  5. Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)

    Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.

  6. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

  7. Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

  8. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.

  9. New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners (HTG281)

    Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.

  10. d-Nav insulin management app for type 2 diabetes (MIB285)

    NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .

  11. Devices for remote monitoring of Parkinson's disease (HTG657)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.

  12. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

  13. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.

  14. Avelumab for previously treated platinum-resistant ovarian cancer ID1497

    In development Reference number: GID-TA10404 Expected publication date: TBC

  15. Suture fixation of acute disruption of the distal tibiofibular syndesmosis (HTG374)

    Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.